Introduction

Nitric oxide exhibits a variety of anti-atherogenic effects such as vasodilation, anti-aggregation, anti-apoptosis, anti-adhesion, anti-proliferation and antioxidation [1]. In common conditions such as hypertension, coronary artery disease and type 2 diabetes, the bioavailability of nitric oxide is reduced, as demonstrated by blunted endothelium-dependent vasodilation [2]. Such endothelial dysfunction is likely a consequence of increased vascular oxidative stress, a condition characterized by a misbalance of endogenous production of vascular reactive oxygen species (ROS) and the vascular antioxidative capacity. Although a variety of mediators have been described to contribute to vascular oxidative stress, both the generation and the detoxification of superoxide most likely play a major role in this process.

Superoxide is generated as a metabolic by-product, for example, in the mitochondria, by cytochrome P450 (CYP) oxygenases, by xanthine oxidase, by nitric oxide synthases (NOS) and particularly by NAD(P)H-oxidases [3]. It is also produced as a signalling molecule for certain cellular processes such as hypertrophy, smooth muscle cell growth, Ras signalling and NFkB activation [4]. There are highly specific mechanisms to rapidly detoxify superoxide and thereby prevent unwanted oxidative processes in...
cells and tissues. Of these, the superoxide dismutases I (CuZnSOD), II (MnSOD) and III (extracellular SOD [ecSOD]) are of utmost importance. Although CuZnSOD and MnSOD provide intracellular and intramitochondrial protection against superoxide, respectively, ecSOD does so in the interstitium. It is expressed in vascular smooth muscle cells and is subsequently secreted to the smooth muscle cell layer of the vascular wall [6]. The highest ecSOD concentrations are found between the endothelial cell layer and the smooth muscle, and 99% of ecSOD is tissue-bound.

Previous investigations have shown that endogenous nitric oxide is an essential stimulus of ecSOD expression in large conductance vessels such as the aorta, and that an increase of endothelial (e)NOS expression by exercise results in a consecutive overexpression of ecSOD [7]. Hence, driving the expression of ecSOD appears to be an important mechanon that underlies the antioxidative effects of nitric oxide. We have also found in several studies that the nitric oxide donors such as pentaerythritol tetranitrate (PETN) [8, 9] and isosorbide mononitrate [10] exert substantial anti-atherosclerotic effects in rabbits, as demonstrated by a reduction in aortic plaque load, an improvement of endothelial function and a reduction of vascular superoxide production. One experimental study reported that PETN increases vascular haemoglobinase expression by approximately 1.5-fold, and it is likely that such a mechanism may play a role in the anti-atherosclerotic effects of PETN [11].

The aim of this study was to investigate whether PETN can increase ecSOD expression and activity in the microvasculature and whether such effects are induced by endogenous nitric oxide, as generated by endothelial-specific overexpression of eNOS as well.

Materials and methods

C57BL/6 mice

A total of 39 C57BL/6 male mice were randomly assigned to three groups and were treated with placebo (PETN-0) and 6 mg (PETN-6) or 60 (PETN-60) mg oral PETN/kg BW/day for 4 weeks. PETN was provided by Actavis, Langenfeld, Germany. Plasma concentrations of pentaerythritol dinitrate (PEDN) and pentaerythritol mononitrate (PEMN) were determined by gas chromatography/mass spectrometry (GC/MS; HP6890; Hewlett-Packard, Boelgen, Germany) after liquid–liquid extraction with ethyl acetate, as described previously [10].

Transgenic eNOS++ mice

Bovine eNOS complementary DNA (cDNA; 4.1 kb) was inserted between the murine Tie-2 promoter (2.1 kb) cDNA and a 10-kb Tie-2 intron fragment, designated as Tie-2-enhancer, and this construct was used to target eNOS gene expression to the vasculature, as described previously [12, 13]. Founder mice showing high eNOS expression (eNOS+++) compared with controls were crossed eight times to C57BL/6 mice to generate a C57BL/6 background. The mice were used at 12–16 weeks of age. Transgene-negative littermates (eNOS−−) served as controls. Permission for the animal studies was provided by the regional government of Germany, and the experiments were performed according to the guidelines for the use of experimental animals, as given by the German “Tierschutzgesetz” and the “Guide for the Care and Use of Laboratory Animals” of the U.S. National Institutes of Health.

Measurement of blood pressure

Systolic blood pressure and heart rate were measured in awake male eNOS++ (n = 6) and eNOS−− (n = 6) mice at 3–4 months of age using an automated tailcuff system (Visitech Systems, Apse, NC, USA), as described previously [14]. On day 6, the mice received N′-nitro-L-arginine (L-NA, Sigma, Munich, Germany) with the drinking water (100 mg L-NA/kg BW/day), and blood pressure measurement was continued for a maximum of 30 days. Blood pressure of PETN-treated mice was measured from the day before treatment until 6 days after treatment.

Determination of ecSOD mRNA concentration

Total RNA was isolated from snap-frozen lung tissue with the QIAshredder and RNeasy kit (Qiagen, Hilden, Germany), including an on-column DNAse digestion. Complementary DNA was synthesized from 1 μg total RNA using the QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer’s protocol. A primer/probe set directed to amplify an 82-bp fragment overlapping the exon2/exon3 boundary was designed with the online software provided by Qiagen (http://www.qiagen.com) and it revealed the following primers: sense: 5′-GTAGATAGTCTGTGCAC-3′; antisense: 5′-CTACATGATACGCTGAG-3′; probe: 5′-TACGGCCCTGCTACTG-3′. For normalization purposes, coamplification of hypoxanthine guanine phosphoribosyltransferase (HPRT) cDNA was performed. The probes for ecSOD and HPRT were labelled with 6-carboxy-fluorescein and Yakima Yellow, respectively. The relative ecSOD expression was determined using the ΔΔCt method. A second set of normalization experiments was based on 18S rRNA or smooth muscle actin (SMA) using 18S rRNA: 5′-ATACAGACCTTCTGAGCCCGC-3′ and 5′-CTGAGACTTGACAGGACACAC-3′; probe: 5′-CTAGCGCTTGCTACTTG-3′. For normalization purposes, coamplification of hypoxanthine guanine phosphoribosyl transferase (HPRT) cDNA was performed. The probes for ecSOD and HPRT were labelled with 6-carboxy-fluorescein and Yakima Yellow, respectively. The relative ecSOD expression was determined using the ΔΔCt method. A second set of normalization experiments was based on 18S rRNA or smooth muscle actin (SMA) using 18S rRNA: 5′-ATACAGACCTTCTGAGCCCGC-3′ and 5′-CTGAGACTTGACAGGACACAC-3′; probe: 5′-CTAGCGCTTGCTACTTG-3′.
Measurement of ecSOD activity

The lungs were homogenized in 50 mM potassium phosphate (pH 7.4) containing 0.3 mol/l potassium bromide, as described previously [16]. Chromatography of homogenates on concanavalin A sepharose (GE Healthcare, Uppsala, Sweden) has been used to separate ecSOD from other SOD isoenzymes [16]. The SOD activity was determined spectrophotometrically by monitoring the inhibition of the rate of xanthine oxidase-mediated reduction of cytochrome C, as described previously [17]. The effectiveness of ecSOD separation was confirmed by Coomassie native gel staining and Western blot analysis. The lungs from 6 individual animals were pooled and two separate pools were analysed.

Statistics

All data were analysed by a standard computer program (GraphPad Prism PC software, version 3.03, Graphpad Software, La Jolla, CA, USA) and are expressed as mean ± S.E.M. of n individual samples. Statistical comparisons between the groups were performed by either the t-tests or the Newman–Keuls multiple comparisons test following one-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant.

Results

PETN metabolites and blood pressure data

The plasma concentrations of PETN metabolites detectable by GC/MS, PEDN and PEMN, rose with the daily oral dose of PETN. PEMN increased from 167.0 ± 104.8 ng/ml (PETN-6, n = 3) to 324.0 ± 48.4 ng/ml (PETN-60, n = 4, P = 0.0509), and PEDN from 17.3 ± 3.3 ng/ml (PETN-6, n = 3) to 120.8 ± 32.7 ng/ml (PETN-60, n = 4, P = 0.0444), indicating successful PETN resorption. Six days of treatment with PETN had no effect on blood pressure in awake mice. In PETN-6 mice (n = 4), the initial blood pressure of 121.8 ± 1.4 mmHg remained unchanged after treatment (119.1 ± 7.7 mmHg, P = 0.7414). Similar results were obtained before (125.0 ± 4.6 mmHg) and after (114.1 ± 8.3 mmHg, P = 0.2915) treatment in PETN-60 mice (n = 4; Fig. 1A). These data suggest that PETN, even at doses exceeding therapeutic doses by 20-fold, had no effect on resting blood pressure in mice.

Blood pressure and eNOS expression in eNOS-overexpressing mice

Systolic blood pressure in eNOS++ mice was reduced (Fig. 1B; P = 0.0126, n = 4). Treatment with the eNOS-inhibitor L-NA increased blood pressure in both eNOS0 and eNOS+++ mice, and the difference between the two groups disappeared after 25 days of L-NA treatment (P = 0.4407, n = 4). Western blot analysis showed increased expression of aortic eNOS protein in eNOS+++ mice of 2.8 ± 0.5-fold (P = 0.0369, n = 4; Fig. 1C).

eSOD mRNA levels

The mRNA expression of lung eSOD relative to HPRT did not show significant changes in the PETN-treated groups compared with the PETN-0-treated groups (each n = 6, P = 0.7568, ANOVA; Fig. 2A). In eNOS+++ mice, ecSOD mRNA expression (0.522 ± 0.080) was not significant different from eNOS0 mice (0.637 ± 0.156, n = 6, P = 0.5238; Fig. 2B). Likewise, eNOS+++ aortic ecSOD mRNA levels were unchanged. Similar results on aortic ecSOD mRNA were obtained after treatment with L-NA and renal SMA and 18S rRNA were used as standards (Fig. 2C).

eSOD protein expression

PETN increased ecSOD protein expression in the lungs to 251 ± 91.0% (n = 5) in the PETN-6 group and to 362 ± 84.9% (n = 6) in the PETN-60 group (n = 6, P = 0.0479 versus PETN-0; Fig 3A). A comparable result was obtained with a polyclonal ecSOD antibody (data not shown). A post-hoc analysis revealed statistical significance for PETN-60 versus PETN-0 but not for PETN-6 versus PETN-0 (Fig. 3A). Similar data were obtained in the aortas of the PETN-treated mice (Fig. 3B). The expression in PETN-6 mice was 152 ± 18.9% (n = 6) and that in PETN-60 was 207 ± 34.7% (n = 5) as compared with PETN-0 mice (P = 0.0116, for ANOVA; * = P < 0.01 for PETN-0 versus PETN-60, post-hoc analysis).

The lung tissue of eNOS+++ mice showed increased ecSOD protein as well (142 ± 10.5%, n = 5, P < 0.05 versus eNOS0). Treatment with L-NA strongly reduced ecSOD expression (P = 0.0003, ANOVA; Fig. 3C) to 59.8 ± 18.6% in eNOS0 mice (n = 6, P < 0.001 versus untreated) and to 44.4 ± 12.0% in eNOS+++ mice (n = 6, P < 0.001 versus untreated). Furthermore, the difference in ecSOD protein expression disappeared (Fig. 3C; P > 0.05 for eNOS+++/L-NA versus eNOS0/L-NA). Additionally, eNOS+++ mice showed increased ecSOD blood plasma levels of 122 ± 5.6% (n = 3, P = 0.0021) compared with eNOS0 mice (Fig. 3D).

eSOD activity

Changes in ecSOD activity paralleled changes in ecSOD expression (n = 7, P < 0.0001, ANOVA; Fig 4A). In the lungs of the PETN-treated mice, the ecSOD activity was 24.2 ± 2.23 U/mg (PETN-6, n = 7, P < 0.05, post-hoc analysis) and 37.3 ± 2.77 U/mg (PETN-60, n = 6, P < 0.01, post-hoc analysis) compared with the ecSOD activity of 16.1 ± 1.95 U/mg in PETN-0 mice. Likewise, the ecSOD activity was significantly increased in eNOS+++ mice (63.5 ± 4.24 U/mg, n = 6) compared with eNOS0 mice (51.3 ± 2.95 U/mg, n = 6, P = 0.0401; Fig. 4B).
Fig. 1 eNOS and blood pressure in eNOS-overexpressing mice. (A) Blood pressure in C57Bl/6 mice before (initial) and after treatment with PETN (not significant). (B) Untreated eNOS++ mice have a significant lower blood pressure than eNOSn (P < 0.05). After 25 days of treatment with the eNOS inhibitor L-NA, this difference disappeared (P > 0.05). (C) Upper panel: Western blot for eNOS in aortic homogenates of eNOS++; lower panel: a mean of 2.8 ± 0.5-fold greater eNOS expression than in eNOSn (n = 4, * = P < 0.05).

Fig. 2 ecSOD mRNA levels. (A) Treatment of C57Bl/6 mice with 6 mg/kg/day (PETN-6) or 60 mg/kg/day (PETN-60) PETN induced no changes in lung ecSOD mRNA expression relative to HPRT (P > 0.05 versus PETN-0). (B) eNOS++ mice induced no changes in lung ecSOD mRNA expression relative to HPRT (P > 0.05 versus eNOSn). (C) eNOS++ mice induced no changes in aortic ecSOD mRNA expression relative to SMA (P > 0.05 versus eNOSn), irrespective of oral treatment with L-NA.
Fig. 3 ecSOD protein expression. (A) Increased ecSOD protein expression in lung cytosolic fractions of C57Bl/6 mice treated with 0, 6 or 60 mg/kg/day PETN (PETN-0, PETN-6 or PETN-60, respectively, * = P < 0.05 for PETN-60 versus PETN-0). (B) Increased ecSOD protein expression in aortic homogenates of PETN-treated mice (* = P < 0.01 versus PETN-0). (C) Increased ecSOD protein expression in lung cytosols of eNOS<sup>−/−</sup> versus eNOS<sup>−/−</sup>/L-NA mice (P < 0.05). Treatment with L-NA significantly lowered ecSOD expression in both groups (eNOS<sup>−/−</sup>/L-NA and eNOS<sup>−/−</sup>/L-NA; each * = P < 0.05 versus eNOS<sup>−/−</sup>) and blunted the difference between both groups (N.S. = P > 0.05). (D) ecSOD protein in blood plasma of eNOS<sup>−/−</sup> mice was significantly increased compared with transgene-negative littermates (eNOS<sup>−/−</sup>, * = P < 0.01).
The aim of this study was to investigate whether vascular expression of ecSOD is subject to genetic and pharmacological regulation. Our findings are that the organic nitrate PETN increases the expression and activity of microvascular and macrovascular ecSOD in mice in vivo, and that a similar increase was observed in expression and activity of microvascular and macrovascular ecSOD in untreated transgenic mice with an endothelium-specific overexpression of bovine eNOS. These data extend previous observations and suggest that increased bioavailability of vascular nitric oxide regulates ecSOD expression, and that this effect might contribute to the antioxidative and anti-atherosclerotic effects of PETN observed previously.

This is the first study that demonstrates that PETN can induce the expression of ecSOD. PETN is an organic nitrate that is known to exert its anti-anginal effect by nitric oxide-dependent activation of soluble guanylyl cyclase (sGC), subsequent cyclic guanosine monophosphate (cGMP)-induced activation of protein kinase G and vasodilation of conductive arteries [18]. There is some debate whether nitric oxide is indeed the pharmacologically active principle of organic nitrates [19], although spin-trap-based nitric oxide analyses in rabbits have demonstrated vascular nitric oxide formation from glyceryl trinitrate in both venous and arterial vessels [20]. Detailed investigations identified a novel reductase activity of mitochondrial aldehyde dehydrogenase as the most important pathway for glyceryl trinitrate bioactivation, whereas nitrite but no nitric oxide was detectable as an intermediate of this reaction [21]. It has been shown that PETN and its trinitrate metabolite PETriN is effectively metabolized by aldehyde dehydrogenase (ALDH)-2 [22], whereas PEDN and PEMN are likely bioactivated by other pathways, for example, in a cytochrome P 450-dependent manner [23, 24]. Thus, there is neither evidence nor reasons to conclude that PETN increases vascular superoxide generation in vivo.

There is evidence that PEMN and PEDN generate nitric oxide. PETN and all metabolites are able to release nitric oxide in a cystein-dependent manner. Likewise, the activation of sGC occurs in a cystein-dependent fashion. Furthermore, there are excellent correlations between cystein-dependent nitric oxide release and in vitro vasodilation expressed as pD2 values [18]. Neither PETN nor PETriN appears in blood plasma, suggesting that PETN and PETriN undergo extensive hepatic metabolism following intestinal absorption, the so-called first-pass effect [25]. Furthermore, intragastral PETN reduced the mean aortic pressure in anaesthetized rabbits by 20%, and the same quantitative effect was measured by intravenous PEDN, suggesting that PEDN is the major vasoactive metabolite [26]. Furthermore, the plasma half-lives of PEDN and PEMN are closely correlated with the duration of the anti-anginal action of PETN [25]. These data strongly suggest that vascular nitric oxide formation from PEDN and PEMN is a prerequisite for the therapeutical efficacy of PETN.

According to the metabolism pathways discussed previously, it seems likely that the up-regulation of ecSOD protein expression was not directly by PETN but rather by nitric oxide released from its metabolites PEDN and PEMN. To further substantiate this, we used our transgenic mouse model with an endothelial overexpression of eNOS. In these mice, overexpression of eNOS was functionally active, as demonstrated by a significant reduction of blood pressure, which was completely blunted by oral treatment with the NOS inhibitor L-NA. We found a significant up-regulation of ecSOD protein expression and activity in cytosols of the lungs and aorta, suggesting that nitric oxide is the active mediator. To further challenge this hypothesis, we treated both eNOS−/− and eNOS−− mice with the NOS inhibitor L-NA and observed a strong down-regulation of ecSOD protein expression. This result provides additional evidence for a regulatory role of vascular nitric oxide for ecSOD protein expression. Likewise, this result demonstrates that the increase of ecSOD in eNOS−− mice is not an unspecific consequence of genetic manipulation. Finally, the reduction of blood pressure itself unlikely influenced the expression of ecSOD. This up-regulation was evident either at reduced blood pressure in eNOS−− mice or at normal blood pressure following PETN treatment.

Our earlier observations with spontaneous nitric oxide donors in smooth muscle cells and aortic organoid cultures and with
exercise in mice in vivo [7] are consistent with the suggestion that nitric oxide is an important mediator driving ecSOD expression. In that same study, it was shown that the effect of nitric oxide on ecSOD expression seems to be cGMP-dependent, as it was prevented by the selective GC inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and was mimicked by a cGMP analogue. So far, it is not known whether other nitric oxide/superoxide interactions such as suppression of thioredoxin-interacting protein [27] or alterations in superoxide release by neutrophils [28] may be involved in or modify ecSOD up-regulation.

In human vascular smooth muscle cells, nitric oxide was shown to increase the transcription but not the half-life of ecSOD mRNA, and the effect on transcription was critically dependent on the activity of p38 mitogen activated protein (MAP) kinase. In contrast to these findings in cultured human cells, we were not able to detect a change in mRNA levels in murine lung and aortic tissue after PETN treatment and in eNOS−/− mice as well. One alternative pathway could be that ecSOD is produced in other organs or tissues and reaches the lungs by travelling through the circulation. In this case, one would expect an increase of circulating ecSOD protein, which was indeed measurable. However, it remains unclear whether the small increase of circulating ecSOD is sufficient to account for the increase of ecSOD found in the aorta and lungs. Alternatively, a yet unresolved, solely post-translational in vivo regulation of ecSOD protein expression might occur. Peng et al. recently showed a nitric oxide-induced inhibition of the ubiquitin–proteasome system in murine primary cortical neurons [29]. Given this, one could speculate that the increase of ecSOD protein expression and activity in vivo could be a yet undiscovered effect of nitric oxide that needs to be substantiated further. However, other studies on this matter have suggested that nitric oxide rather increases proteasomal degradation of proteins by nitric oxide-dependent protein modification such as S-nitrosylation [30]. Taken together, established mechanisms of ecSOD regulation like the influence of proteolytic removal of the heparin-binding domain [31] and inflammatory cytokines [32] might extend to a yet unknown nitric oxide-dependent mechanism that deserves further interest and investigation.

Up-regulation of ecSOD likely appears to be a mechanism that contributes to the antioxidative and anti-atherosclerotic effects of PETN observed previously. PETN was shown to reduce the development and progression of experimental atherosclerosis [8], and this effect was evident even in established atherosclerosis [9]. Further activities of PETN such as inhibition of endothelial dysfunction and LDL oxidation are consistent with an inhibition of superoxide formation as well [9], although it is not sure that the observed effect is active in a similar manner in pathological settings. Additionally, PETN does not induce the development of in vivo nitrate tolerance [18], which strikingly contrasts the effect of glyceryl trinitrate, which is a well-known inducer of nitrate tolerance associated with increased vascular oxidative stress [33]. The lack of nitrate tolerance induction by PETN was shown in experimental [26, 34] and clinical studies [35]. Hence, the increased expression of ecSOD might contribute to the lack of nitrate tolerance induction by PETN as well.

By induction of ecSOD expression, PETN likely increases the bioavailability of endogenous nitric oxide, as superoxide and nitric oxide rapidly form peroxynitrite, a strong oxidant contributing to vascular oxidative stress and a source for further reactive radicals. These related products involve peroxynitrous acid or decomposition products of the carbon dioxide adduct of peroxynitrite such as the nitrogen dioxide radical [36–38]. However, superoxide is rapidly detoxified to hydrogen peroxide, which has been shown to induce both the expression and the activity of eNOS [39]. Thus, a higher activity of ecSOD will not only reduce extracellular superoxide but also protect readily formed nitric oxide. By increasing hydrogen peroxide, it most likely increases endothelial nitric oxide synthesis as well. This effect of hydrogen peroxide has been shown to contribute to the up-regulation of vascular nitric oxide synthesis induced by exercise training [12].

Acknowledgements

We like to thank Dr. Dirk Stalleicken (Actavis Deutschland GmbH & Co. KG, Langenfeld, Germany) for providing PETN. This study was supported by the Forschungskommission of the Heinrich-Heine-Universität Düsseldorf (Project 9772 109 to GK and project 9772 345 to TS). GK has received an educational grant from Actavis GmbH, Germany.

References

1. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res. 2002; 55: 250–60.
2. Kojda G, Harrison DG. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999; 43: 562–71.
3. Grienglking KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.
4. Grienglking KK, Harrison DG. Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest. 2001; 108: 1423–4.
5. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol. 1995; 15: 2032–6.
6. Jung O, Marklund SL, Geiger H, et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res. 2003; 93: 622–9.
7. Fukai T, Siegfried MR, Ushio-Fukai M, et al. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest. 2000; 105: 1631–9.
8. Kojda G, Stein D, Kottenberg E, et al. In vivo effects of pentaerythritol-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 1995; 25: 763–73.
9. Hacker A, Müller S, Meyer W, Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol. 2001; 132: 1707–14.

10. Muller S, Konig I, Meyer W, Kojda G. Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol. 2004; 44: 624–31.

11. Wenzel P, Oelze M, Coldewey M, et al. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol. 2007; 27: 1729–35.

12. Lauer N, Suvorova T, Rüther U, et al. Critical involvement of hydrogen peroxide in exercise-induced upregulation of endothelial NO-synthase. Cardiovasc Res. 2005; 65: 254–62.

13. Suvorova T, Lauer N, Kumpf S, et al. Endogenous vascular hydrogen peroxide regulates arteriolar tension in vivo. Circulation. 2005; 112: 2487–95.

14. Kojda G, Laursen JB, Ramasamy S, et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res. 1999; 42: 206–13.

15. Koelsling D. Modulators of soluble guanylyl cyclase. Naunyn Schmiedebergs Arch Pharmacol. 1998; 358: 123–6.

16. Marklund SL. Extracellular superoxide dismutase. Methods Enzymol. 2002; 349: 74–80.

17. Crapo JD, McCord JM, Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol. 1978; 53: 382–93.

18. Kojda G, Hacker A, Noack E. Effects of non- intermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and vascular superoxide production. Eur J Pharmacol. 1998; 355: 23–31.

19. Kleschyov AL, Oelze M, Dalber A, et al. Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res. 2003; 93: e104–12.

20. Müller A, Mordvinov P, Bassenge E, et al. In vivo spin trapping of glycercy trinitrate-derived nitric oxide in rabbit blood vessels and organs. Circulation. 1995; 92: 1876–82.

21. Chen Z, Zhang J, Stampler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002; 99: 8306–11.

22. Wenzel P, Hink U, Oelze M, et al. Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH2- deficient mice. Br J Pharmacol. 2007; 150: 526–33.

23. Minamiyama Y, Takemura S, Akiyama T, et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999; 452: 165–9.

24. McGuire JJ, Anderson DJ, McDonald BJ, et al. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate bio-transformation by diphenyleneiodonium sulfate. Biochem Pharmacol. 1998; 56: 881–93.

25. Weber W, Michaelis K, Luckow V, et al. Pharmacokinetics and bioavailability of pentaerythritol tetranitrate and two of its metabolites. Arzneim Forsch. 1995; 45: 781–4.

26. Mullenheim J, Muller S, Laber U, et al. The effect of high-dose pentaerythritol tetranitrate on the development of nitrate tolerance in rabbits. Naunyn Schmiedebergs Arch Pharmacol. 2001; 364: 269–75.

27. Schulze PC, Liu H, Choe E, et al. Nitric oxide-dependent suppression of thioridoxin-interacting protein expression enhances thioridoxin activity. Arterioscler Thromb Vasc Biol. 2006; 26: 2666–72.

28. Siminiak T, Abramowska A, Czechowska K, et al. Intravenous isosorbide dinitrate inhibits neutrophil aggregation and plasma-mediated stimulation of superoxide anion production. Int J Cardiol. 1994; 45: 171–5.

29. Peng ZF, Chen MJ, Yap YW, et al. Proteasome inhibition: an early or late event in nitric oxide-induced neuronal death? Nitric Oxide. 2008; 18: 136–45.

30. Lee CM, Kim BY, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem. 2008; 283: 889–98.

31. Enghild JJ, Thogersen IB, Dury TD, et al. The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. J Biol Chem. 1999; 274: 14818–22.

32. Stralin P, Marklund SL. Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smooth muscle cells. Atherosclerosis. 2000; 151: 433–41.

33. Münzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995; 95: 187–94.

34. Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythritol tetranitrate. J Cardiovasc Pharmacol. 1997; 30: 831–6.

35. Jurt U, Gori T, Ravandi A, et al. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol. 2001; 38: 854–9.

36. Bonini MG, Radi R, Ferrer-Sueta G, et al. Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide. J Biol Chem. 1999; 274: 10802–6.

37. Lyman SV, Hurst JK. Rapid reaction between peroxonitrite and carbon dioxide: implications for biological activity. J Am Chem Soc. 1995; 117: 8867–8.

38. Pfeiffer S, Mayer B, Hemmens B. Nitric oxide: chemical puzzles posed by a biological messenger. Angew Chem Int Ed. 1999; 38: 1714–31.

39. Drummond GR, Cai H, Davis ME, et al. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res. 2000; 86: 347–54.